Device Promotional Activities Monitored By Competitors, May Hike Costs
This article was originally published in The Gray Sheet
Executive Summary
FDA's slowed pace in dealing with advertising and promotion violations may lead to added costs for manufacturers opting to tap their own funds to take action against perceived violations by competitors